NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01456351,Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab,https://clinicaltrials.gov/study/NCT01456351,,COMPLETED,The study addresses the question if a therapy with bendamustine plus rituximab is comparable (non inferior) with the well-tried combination of fludarabine plus rituximab with regard to event free survival (EFS) in recurrent low malignant Non-Hodgkin and mantle cell lymphomas.,NO,Non-Hodgkin's Lymphoma|Mantle Cell Lymphoma,DRUG: Bendamustine plus Rituximab|DRUG: Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w,"Event Free Survival, From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year, Observation till event or death, minimum 1 year","Remission Rates, From date of randomization until the date of first documented progression, date of detection of a secondary malignancy or date of death from any cause, whichever came first. Minimum 1 year, Observation till event or death, minimum 1 year",,University of Giessen,,ALL,"ADULT, OLDER_ADULT",PHASE3,230,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,NHL 2-2003,2003-09,2010-08,2010-12,2011-10-20,,2024-08-22,"StiL Head Office; Justus-Liebig-University, Giessen, 35392, Germany",
